Shares of Alembic Pharmaceuticals dipped 3 per cent to Rs 998 on the BSE in early morning trade on Wednesday, down 7 per cent in past two days, after the company reported a mixed bag of December quarter (Q3FY21) results. The company’s consolidated revenues grew 8.7 per cent year-on-year (YoY) to Rs 1,314 crore on the back of strong growth in domestic, ROW formulations and API segment. However, US sales growth remained muted, down 0.6 per cent YoY at Rs 512 crore due to competition in Sartans. The consolidated net profit jumped 25 per cent YoY to Rs 293 crore. EBITDA (earnings before interest, taxes, depreciation, and amortization) margins expanded 89 basis points (bps) YoY to 27.8 per cent due to better gross margins and lower R&D cost.